Clinical Trials Browser

Phase 1 × Withdrawn × olaparib × Clear all

NCT05807126 2024-05-02

Testing the Addition of Immunotherapy With Hu5F9-G4 (Magrolimab) to the Usual PARP Inhibitor, Olaparib for Treatment of Metastatic or Recurrent Breast or Castrate-Resistant Prostate Cancer With BRCA Mutations

Phase 1 Withdrawn

Prostatic Neoplasms

NCT02686008 2020-01-13

Pharmacodynamic Study to Assess the Anti-proliferative Activity of the PARP Inhibitor Olaparib in Patients With HPV Positive and HPV Negative HNSCC

Phase 1 Withdrawn

Squamous Cell Carcinoma of Head and Neck

NCT03575078 2019-09-25

ARQ761 + PARP Inhibitor in Refractory Solid Tumors

Phase 1 Withdrawn

Lymphoma